What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
Book Your Appointment at Pure Med Spa Chicago Today At Pure Med Spa Chicago , we specialize in providing high-quality weight loss solutions, including Semaglutide and Tirzepatide treatments
in the case of Mod GRF 1-29, numerous daily injections are required
I'm especially interested in the potential cognitive benefits of GLP-1s beyond their metabolic effects